The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
About this episode
This episode discusses the challenges and advances in managing Neurofibromatosis Type 1 and its associated plexiform neurofibromas in both pediatric and adult populations.
| Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging clinical trial data into everyday practice, particularly in identifying candidates for mitogen-activated protein kinase inhibitors, managing ...
More episodes of CEConversations
- A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC
- Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies
- Targeting the Pathway: Evolving Roles of MEK Inhibitors in NF1-Associated PN
- Evolving Paradigms in Immuno-Oncology: Optimizing Patient Care Through Innovative Delivery Approaches of Immune Checkpoint Inhibitors
- MEK Inhibitors in Neurofibromatosis Type 1: Nursing Contributions to NF1-PN Management
- Desmoid Tumors in Focus: Early Recognition, Evolving Therapies, and Nursing-Led Care Strategies
Explore listener stats, chart rankings, contacts and more on the CEConversations podcast page.